Discovery of New VEGFR-2 Inhibitors and Apoptosis inducer-based thieno[2,3-d]pyrimidine

References

• Biemar F , FotiM. Global progress against cancer – challenges and opportunities. Cancer Biol. Med.10(4), 183 (2013).
   PubMedGoogle Scholar
• Ward RA , FawellS, Floc'hN, FlemingtonV, McKerrecherD, SmithPD. Challenges and opportunities in cancer drug resistance. Chem. Rev.121(6), 3297–3351 (2020).
   PubMed Web of Science ®Google Scholar
• Trenker R , JuraN. Receptor tyrosine kinase activation: from the ligand perspective. Curr. Opin. Cell Biol.63, 174–185 (2020).
   PubMed Web of Science ®Google Scholar
• Wang X , BoveAM, SimoneG, MaB. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front. Cell Dev. Biol.8, 1–12 (2020).
   PubMed Web of Science ®Google Scholar
• Modi SJ , KulkarniVM. Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective. Med. Drug Discov.2, 100009 (2019).
   Google Scholar
• Silva SR , BowenKA, RychahouPGet al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int. J. Cancer128(5), 1045–1056 (2011).
   PubMed Web of Science ®Google Scholar
• Nishida N , YanoH, NishidaT, KamuraT, KojiroM. Angiogenesis in cancer. Vasc. Health Risk Manag.2(3), 213 (2006).
   PubMedGoogle Scholar
• Xie Q-Q , XieH-Z, RenJ-X, LiL-L, YangS-Y. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. J. Mol. Graph.27(6), 751–758 (2009).
   Google Scholar
• Lee K , JeongK-W, LeeYet al. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur. J. Med. Chem.45(11), 5420–5427 (2010).
   PubMed Web of Science ®Google Scholar
• Eskander RN , TewariKS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma – mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol. Oncol.132(2), 496–505 (2014).
   PubMed Web of Science ®Google Scholar
• Machado VA , PeixotoD, CostaRet al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl] ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg. Med. Chem.23(19), 6497–6509 (2015).
   PubMed Web of Science ®Google Scholar
• Wang Z , WangN, HanSet al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLOS ONE8(7), e68566 (2013).
   PubMed Web of Science ®Google Scholar
• Dietrich J , HulmeC, HurleyLH. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796. Bioorg. Med. Chem.18(15), 5738–5748 (2010).
   PubMed Web of Science ®Google Scholar
• Yousef RG , ElwanA, GobaaraIMet al. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies. J. Enzyme Inhib. Med. Chem.37(1), 2206–2222 (2022).
   PubMed Web of Science ®Google Scholar
• Yousef RG , IbrahimA, KhalifaMMet al. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J. Enzyme Inhib. Med. Chem.37(1), 1389–1403 (2022).
   PubMed Web of Science ®Google Scholar
• Elkaeed EB , YousefRG, ElkadyHet al. Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: in vitro anticancer and VEGFR-2 inhibitory effects. Molecules27(14), 4606 (2022).
   PubMed Web of Science ®Google Scholar
• Elkaeed EB , YousefRG, ElkadyHet al. The assessment of anticancer and VEGFR-2 inhibitory activities of a new 1H-indole derivative: in silico and in vitro approaches. Processes10(7), 1391 (2022).
   Web of Science ®Google Scholar
• Taghour MS , ElkadyH, EldehnaWMet al. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J. Enzyme Inhib. Med. Chem.37(1), 1903–1917 (2022).
   PubMed Web of Science ®Google Scholar
• Taghour MS , ElkadyH, EldehnaWMet al. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway. J. Enzyme Inhib. Med. Chem.17(9), e0272362 (2022).
   Google Scholar
• Yousef RG , ElkadyH, ElkaeedEBet al. (E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido) benzoyl) hydrazono) ethyl) phenyl) nicotinamide: a novel pyridine derivative for inhibiting vascular endothelial growth factor receptor-2: synthesis, computational, and anticancer studies. Molecules27(22), 7719 (2022).
   PubMed Web of Science ®Google Scholar
• Eldehna WM , Abo-AshourMF, NocentiniAet al. Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene) thiazolidin-2-ylidene) amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies. Eur. J. Med.Chem.139, 250 (2017).
   PubMed Web of Science ®Google Scholar
• Taghour MS , ElkadyH, EldehnaWMet al. Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies. J. Biomol. Struct. Dyn.1–16 (2022).
   Google Scholar
• Elkaeed EB , TaghourMS, MahdyHAet al. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. J. Enzyme Inhib. Med. Chem.37(1), 2191–2205 (2022).
   PubMed Web of Science ®Google Scholar
• Elrazaz EZ , SeryaRA, IsmailNS, AbouEl Ella DA, AbouzidKA. Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. Future J. Pharm. Sci.1(2), 33–41 (2015).
   Google Scholar
• Yang C-R , PengB, CaoS-Let al. Synthesis, cytotoxic evaluation and target identification of thieno[2,3-d]pyrimidine derivatives with a dithiocarbamate side chain at C2 position. Eur. J. Med. Chem.154, 324–340 (2018).
   PubMed Web of Science ®Google Scholar
• Ali EM , Abdel-MaksoudMS, OhC-H. Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: recent advances. Bioorg. Med. Chem.27(7), 1159–1194 (2019).
   PubMed Web of Science ®Google Scholar
• Sequist LV , BesseB, LynchTJet al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.28(18), 3076–3083 (2010).
   PubMed Web of Science ®Google Scholar
• Kim Y , KoJ, CuiZet al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther.11(3), 784–791 (2012).
   PubMed Web of Science ®Google Scholar
• Elmetwally SA , SaiedKF, EissaIH, ElkaeedEB. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg. Chem.88, 102944 (2019).
   PubMed Web of Science ®Google Scholar
• Sobh EA , DahabMA, ElkaeedEBet al. Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-d]pyrimidine derivatives as new EGFR inhibitors. J. Enzyme Inhib. Med. Chem.38(1), 2220579 (2023).
   PubMed Web of Science ®Google Scholar
• Sobh EA , DahabMA, ElkaeedEBet al. Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket. J. Biomol. Struct. Dyn.1–23 (2023).
   PubMedGoogle Scholar
• El-Metwally SA , Abou-El-RegalMM, EissaIHet al. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg. Chem.112, 104947 (2021).
   PubMed Web of Science ®Google Scholar
• Sobh EA , DahabMA, ElkaeedEBet al. A novel thieno[2,3-d]pyrimidine derivative inhibiting vascular endothelial growth factor receptor-2: a story of computer-aided drug discovery. Drug Dev. Res.84(6), 1247–1265 (2023).
   PubMed Web of Science ®Google Scholar
• Yousef RG , SakrHM, EissaIHet al. New quinoxaline-2(1H)-ones as potential VEGFR-2 inhibitors: design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J. Chem.45(36), 16949–16964 (2021).
   Web of Science ®Google Scholar
• Alanazi MM , ElkadyH, AlsaifNAet al. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv.11(48), 30315–30328 (2021).
   PubMed Web of Science ®Google Scholar
• Elkady H , El-DardirOA, ElwanAet al. Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2, 4-dione derivatives as potential antitumor VEGFR-2 inhibitors. RSC Adv.13(40), 27801–27827 (2023).
   PubMed Web of Science ®Google Scholar
• Hagras M , SalehMA, EzzEldin RRet al. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. J. Enzyme Inhib. Med. Chem.37(1), 386–402 (2022).
   Web of Science ®Google Scholar
• Gewald K , SchinkeE, BöttcherH. Heterocyclen aus CH-aciden Nitrilen, VIII. 2-Amino-thiophene aus methylenaktiven Nitrilen, Carbonylverbindungen und Schwefel. Eur. J. Inorg. Chem.99(1), 94–100 (1966).
   Google Scholar
• Di Fruscia P , ZacharioudakisE, LiuCet al. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4 (3H)-one SIRT2 Inhibitor that is neuroprotective in an in vitro Parkinson's disease model. ChemMedChem10(1), 69–82 (2015).
   PubMed Web of Science ®Google Scholar
• Aruna Kumari M , TriloknadhS, HarikrishnaN, VijjulathaM, Venkata RaoC. Synthesis, antibacterial activity, and docking studies of 1,2,3-triazole-tagged thieno[2,3-d]pyrimidinone derivatives. J. Heterocycl. Chem.54(6), 3672–3681 (2017).
   Web of Science ®Google Scholar
• Ghorab M , AbdelHamide S. Synthesis and effect of gamma radiation on some sulfur containing 3-substituted-4-oxo-2,4,5,6,7,8-hexahydrobenzo[b]thieno-[2,3-d]pyrimidines of biological interest. Phosphorus Sulfur Silicon Relat Elem106(1–4), 9–20 (1995).
   Web of Science ®Google Scholar
• Ma L , XieC, MaYet al. Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases. J. Med. Chem.54(7), 2060–2068 (2011).
   PubMed Web of Science ®Google Scholar
• Ma L , LiS, ZhengHet al. Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease. Eur. J. Med. Chem.46(6), 2003–2010 (2011).
   PubMed Web of Science ®Google Scholar
• Slater T , SawyerB, SträuliU. Studies on succinate-tetrazolium reductase systems: III. Points of coupling of four different tetrazolium salts III. Points of coupling of four different tetrazolium salts. Biochim. Biophys. Acta77, 383–393 (1963).
   PubMed Web of Science ®Google Scholar
• Van De Loosdrecht A , BeelenR, OssenkoppeleG, BroekhovenM, LangenhuijsenMJ. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J. Immunol. Methods174(1–2), 311–320 (1994).
   PubMed Web of Science ®Google Scholar
• Alley MC , ScudieroDA, MonksAet al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res.48(3), 589–601 (1988).
   PubMed Web of Science ®Google Scholar
• Elkaeed EB , YousefRG, ElkadyHet al. In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative. J. Biomol. Struct. Dyn.41(16), 7986–8001 (2022).
   PubMed Web of Science ®Google Scholar
• Eissa IH , YousefRG, ElkadyHet al. Anti-breast cancer potential of a new xanthine derivative: in silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies. Pathol. Res. Pract.251(1), 154894–154911 (2023).
   PubMedGoogle Scholar
• Taghour MS , MahdyHA, GomaaMHet al. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation. J. Enzyme Inhib. Med. Chem.37(1), 2063–2077 (2022).
   PubMed Web of Science ®Google Scholar
• Abraham MJ , MurtolaT, SchulzRet al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. Softwarex1, 19–25 (2015).
   Google Scholar
• Jo S , ChengX, IslamSMet al. CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues. Adv. Protein Chem. Struct. Biol.96, 235–265 (2014).
   PubMed Web of Science ®Google Scholar
• Lee J , ChengX, SwailsJMet al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM 36 additive force field. Biophys. J.12(1), 405–413 (2016).
   Google Scholar
• Tuccinardi T . What is the current value of MM/PBSA and MM/GBSA methods in drug discovery?Expert Opin. Drug Discov.16(11), 1233–1237 (2021).
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco MS , Valdés-TresancoME, ValientePA, MorenoEJ. Computation. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput.17(10), 6281–6291 (2021).
   PubMed Web of Science ®Google Scholar
• Bouysset C , FiorucciS. ProLIF: a library to encode molecular interactions as fingerprints. J. Cheminformatics13, 1–9 (2021).
   PubMed Web of Science ®Google Scholar
• Salentin S , SchreiberS, HauptVJ, AdasmeMF, SchroederM. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res.43(W1), W443–W447 (2015).
   PubMed Web of Science ®Google Scholar
• Tubiana T , CarvailloJ-C, BoulardY, BressanelliS. TTClust: a versatile molecular simulation trajectory clustering program with graphical summaries. J. Chem. Inf. Model58(11), 2178–2182 (2018).
   PubMed Web of Science ®Google Scholar
• Amadei A , LinssenAB, BerendsenHJ. Essential dynamics of proteins. Proteins17(4), 412–425 (1993).
   PubMed Web of Science ®Google Scholar
• Papaleo E , MereghettiP, FantucciP, GrandoriR, DeGioia L. Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. J. Mol. Graph.27(8), 889–899 (2009).
   Google Scholar
• Maisuradze GG , LeitnerDM. Free energy landscape of a biomolecule in dihedral principal component space: sampling convergence and correspondence between structures and minima. Proteins67(3), 569–578 (2007).
   PubMed Web of Science ®Google Scholar
• Hess B . Similarities between principal components of protein dynamics and random diffusion. Phys. Rev. E62(6), 8438 (2000).
   Web of Science ®Google Scholar
• Yousef RG , ElwanA, GobaaraIMet al. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies. J. Enzyme Inhib. Med. Chem.37(1), 2206–2222 (2022).
   PubMed Web of Science ®Google Scholar
• Elkady H , AbuelkhirAA, RashedMet al. New thiazolidine-2, 4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies. Comput. Biol. Chem.107,107958–107984 (2023).
   PubMed Web of Science ®Google Scholar
• Taghour MS , ElkadyH, EldehnaWMet al. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2, 4-diones targeting VEGFR-2 and apoptosis pathway. PLOS ONE17(9), e0272362 (2022).
   PubMed Web of Science ®Google Scholar
• Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods65(1–2), 55–63 (1983).
   PubMed Web of Science ®Google Scholar
• Belal A , AbdelGawad NM, MehanyABet al. Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1,4]diazepine derivatives as potent EGFR/CDK2 inhibitors. J. Enzyme Inhib. Med. Chem.37(1), 1884–1902 (2022).
   PubMedGoogle Scholar
• Adan A , AlizadaG, KirazY, BaranY, NalbantA. Flow cytometry: basic principles and applications. Crit. Rev. Biotechnol.37(2), 163–176 (2017).
   PubMed Web of Science ®Google Scholar
• Wlodkowic D , SkommerJ, DarzynkiewiczZ, Flow cytometry-based apoptosis detection. Apoptosis Methods and Protocols.Springer Dordrecht Heidelberg, London, New York, 2nd, 79–131 (2009).
   Google Scholar
• Lanka G , BegumD, BanerjeeS, AdhikariN, YogeeswariP, GhoshB. Pharmacophore-based virtual screening, 3D QSAR, docking, ADMET, and MD simulation studies: an in silico perspective for the identification of new HDAC3 potential inhibitors. Comput. Biol. Med.166, 107481 (2023).
   PubMed Web of Science ®Google Scholar
• Husein DZ , HassanienR, KhamisM. Cadmium oxide nanoparticles/graphene composite: synthesis, theoretical insights into reactivity and adsorption study. RSC Adv.11(43), 27027–27041 (2021).
   PubMed Web of Science ®Google Scholar
• Wang T , HuseinD. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: disposing of waste with waste. Environ. Sci. Pollut. Res.30(4), 8928–8955 (2023).
   PubMed Web of Science ®Google Scholar
• Waring MJ , ArrowsmithJ, LeachARet al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov.14(7), 475–486 (2015).
   PubMed Web of Science ®Google Scholar
• Ferreira LL , AndricopuloAD. ADMET modeling approaches in drug discovery. Drug Discov. Today24(5), 1157–1165 (2019).
   PubMed Web of Science ®Google Scholar
• Kar S , LeszczynskiJ. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin. Drug Discov.15(12), 1473–1487 (2020).
   PubMed Web of Science ®Google Scholar
• Moroy G , MartinyVY, VayerP, VilloutreixBO, MitevaM. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov. Today17(1–2), 44–55 (2012).
   PubMed Web of Science ®Google Scholar